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ABSTRACT
Human endogenous retroviruses (HERVs) can be
divided into distinct families of tens to thousands of
paralogous loci. The expression of HERV elements
has been detected in all tissues tested to date, par-
ticularlygermcells,embryonictissuesandneoplastic
tissues. Hence, the study of HERV expression could
represent added value in cancer diagnosis. We
developedaquantitativeassaycombiningamultiplex
degenerate PCR (MD-PCR) amplification, based on
the relative conservation of the pol genes, and a
colorimetric Oligo Sorbent Array (OLISA ). Nine
HERV families were selected and amplification
primers and capture probes were designed for each
family. The features required to achieve efficient
amplification of most of the elements of each HERV
family and balanced co-amplification of all HERV
familieswereanalyzed.WefoundthatMD-PCRreliab-
ility, i.e. equivalence of amplification and dose-effect
relationship, relied on the adjustment of three critical
parameters: the primer degeneracy, the relative
concentration of each primer and the total amount
of primers in the amplification mixture. The analysis
of tumoral versus normal tissues suggests that this
assay could prove useful in tumor phenotyping.
INTRODUCTION
Human endogenousretroviruses(HERVs)constituteabout8%
of the human genome (1). HERVs are considered as remnants
of past germ-cell line infections by retroviruses that occurred
during mammal evolution. Phylogenetic studies have identi-
ﬁed at least 31 different HERV families each encompassing
tenstothousands ofloci(2)which aretheresultofintracellular
retrotransposition of transcriptionally active copies. All are
defective for viral replication due to genetic drift and are,
as a result, transmitted in a Mendelian fashion. Research
over the past two decades has demonstrated that HERVs
may have biological functions. It has been suggested that
HERVs could be involved in genome shaping as potential
chromosomal recombination sites (3). HERV long terminal
repeats (LTR), whose original function is retroviral expression
control, could provide transcriptional regulatory elements
for cellular genes consisting in promoter (4), enhancer (5)
or polyadenylation signal functions (6). HERV proteins
could also have biological functions as illustrated by the
ERVWE1 Env protein, also known as syncytin (7–10).
HERV expression was particularly investigated in three
speciﬁc contexts, i.e. placentation (11,12), auto-immunity
(13,14) and cancer (15,16) that are associated with cellular
differentiation or immunity modulation. However, it is still
generally unclear whether HERVs are triggers or markers in
pathological contexts, although it has been suggested that Env
HERV-W and Rec HERV-K are involved in multiple sclerosis
(17,18) and testicular tumorigenesis (19,20), respectively.
Quantitative approaches concerning both HERV transcripts
could thus represent added value in current cancer and chronic
disease diagnosis. On the basis of functional hypotheses
associated with candidate loci, the majority of HERV quanti-
tative expression studies are based on RT–PCR (11,21–23).
Nevertheless, global approaches representing the activity of
HERV families may elucidate the mechanisms involved in
transcriptional regulation and address physio-pathological
functions.
These approaches would consist in analyzing either the
expression of each locus within each family or, alternatively,
the overall transcription of each family. The ﬁrst approach is
challenging in terms of speciﬁcity due to the features of these
repeated elements. The second approach could be tackled in
two ways, (i) by developing different HERV-taxon speciﬁc
real-time RT–PCR assays using consensus (24) or degenerate
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doi:10.1093/nar/gkl086primers (25) or (ii) by developing a quantitative assay
combining multiplex degenerate PCR (MD-PCR) with an
oligonucleotide microarray. This could be achieved subject
to minimized bias, i.e. efﬁcient ampliﬁcation of most of
the elements of each family and balanced co-ampliﬁcation
of each family. In this way, the retrovirus pol genes
reverse-transcriptase region encompasses two conserved
sequences, corresponding to the VLPQG and YV/MDDI/V/LL
amino-acid motifs, which enabled the development of pan-
retrovirus ampliﬁcations using degenerate primers. The ﬁrst
pan-retrovirus PCR assay developed by Shih in 1989 (26) was
based on a single pair of degenerate primers. This system was
improved by adding a semi-nested PCR step (27) which
enabled the detection of HERV-W expression in the serum
of multiple sclerosis patients (28). Nevertheless, it was estab-
lished that this system failed to detect the expression of
another HERV family (HERV-H) due to a biased degenerate
primer composition (29). More sophisticated systems were
developed in order to identify all known retroviral reverse-
transcriptase sequences. Independent ampliﬁcations of beta
and gamma retroviruses were obtained initially using two
pairs of degenerate primers (30) and at the present time
using two complex primer mixtures (31). Interestingly, the
report of a broad consistency between the latter qualitative
assay and quantitative RT–PCR ampliﬁcations (24) suggests
that a pan-retrovirus-based procedure could be suitable as a
quantitative assay.
In this paper, we describe the development of a pan-
retrovirus PCR ampliﬁcation dedicated to the analysis of
differential HERV expression proﬁles. This aim essentially
requires the deﬁnition of a quantitative method to evaluate
HERV expression. Nine HERV families were selected
according to their transcriptional activity in various physio-
pathological contexts (HML-2, HML-4, HERV-H, ERV-9,
HERV-W, HERV-E4.1 and HERV-R) (32), their sequence
homology with infectious retroviruses (HML-5) (33) or
their genomic complexity (HERV-L) (34). These families
belongtothreedistinctclassesofretroviruses:betaretroviruses
(HML-2, HML-4 and HML-5), gammaretroviruses (HERV-H,
ERV-9, HERV-W, HERV-E4.1 and HERV-R) and spuma-
viruses (HERV-L). We systematically investigated the key
factors involved in the efﬁcient co-ampliﬁcation of the nine
HERV families. Biotinylated PCR products were quantiﬁed
using an Oligo Sorbent Array (OLISA ) low-density plastic
microarray derived from our Enzyme-linked Oligo Sorbent
Assay (ELOSA) developed for the detection and quantitation
of HIV1 provirus (35,36). Three parameters were found to be
critical in order to obtain an almost equivalent ampliﬁcation
efﬁciency of the different targets and dose-effect relationship:
the primer degeneracy level, the relative concentration of each
primer and the total amount of primers in the ampliﬁcation
mixture. Finally, the MD-PCR/OLISA assay was used to
compare HERV transcript content in differentiation models
and in tumoral versus normal RNA samples.
MATERIALS AND METHODS
Collection of HERV elements
HERV-related sequences were collected from GenBank
with RepeatMasker (Smit, AFA, Hubley, R & Green, P.
RepeatMasker Open-3.0. 1996–2004 http://www.
repeatmasker.org) using a 20% divergence threshold. The
query library contained pol reference sequences of the nine
HERV families, deﬁned as HML-2 (accession no. Y17832,
position 4557–7175), HML-4 (AF020092, 3884–6998),
HML-5 (AC004536, 36 079–38 642), HERV-H (AJ289709,
2458–6015), ERV-9 (Z84475, 28 749–32 286), HERV-W
(AC000064, 32 379–35 878), HERV-E4.1 (M10976,
2650–6210), HERV-R (AC073210, 57 299–60 388),
HERV-L (X89211, 2249–5807). Alignments were performed
with ClustalW (37) and adjusted manually with the Seaview
multiple alignment editors (38). A matrix indicating the
occurrence of each nucleotide for each pol position was
generated in order to design ampliﬁcation primers and
detection probes.
Cloning of HERV-pol archetypes
HERV proviruses were ampliﬁed from genomic DNA by
means of long-PCR as described previously (10) and pol
archetypes were then cloned and sequenced after a nested
PCR step. Final HERV archetypes were: HML-2 chromosome
7 from base 103 983 434 to 103 984 261, HML-4 chromosome
10 from base 5 074 724 to 5 075 458, HML-5 chromosome 7
from base 117 350 949 to 117 351 816, HERV-H chromosome
2 from base 166 394 420 to 166 395 285, ERV-9 chromosome
6 from base 115 664 573 to 115 665 345, HERV-W chromo-
some 7 from base 91 746 541 to 91 747 359, HERV-E4.1
chromosome 19 from base 20 726 359 to 20 727 215, HERV-R
chromosome 7 from base 63 899 936 to 63 900 787 and
HERV-L chromosome 16 from base 59 440 954 to 59 441 771.
Probe design and microarray setup
Fifteen 20–25mer probes corresponding to the nine HERV
families were designed within the pol ampliﬁed region
(probe sequences available upon request). For each HERV
family, consensus probes were determined using the pol
sequence matrix. In addition, for the HML-2 capture probe,
positions 12, 6, 19, 22 and 3 were cumulatively changed into
cytosine to generate from one to ﬁve mismatch-containing
probes. This type of probe was also designed for HERV-H
by mutating the 9th position. The OLISA  microarrays (39)
were purchased from bioMe ´rieux (Grenoble, France). They
consisted of 8-well plastic modules in which the probes
were spotted in a circular format and tethered onto the support
by a 50 aminated end (Figure 1A). Probe speciﬁcity was
assessed by hybridization with biotinylated transcripts pro-
duced from cloned archetypes. HML-2 and HERV-H variant
probes were used to evaluate the mismatch impact on target
hybridization. The ﬁnal version of the microarray used to
analyzebiologicalsamplescontainedHERV speciﬁc validated
probes and HIV1- and HTLV1-negative controls.
Primer design
Degenerate primer pairs were designed in a highly conserved
region of the pol gene RT sub-region. For each of the nine
HERV families investigated in the study, the primer sequences
were determined according to the corresponding pol sequence
matrix. The levels of degeneracy were deﬁned in line with the
general parsimony principle highlighted in this study. The
ampliﬁcation efﬁciency and speciﬁcity of each degenerate
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before collecting them to form a global primer mix.
HERV-L-specific amplification
HERV-L PCR ampliﬁcations with a weakly-degenerate
(Forward tttactgtcctacytcagggr, Reverse tcarcataatgycat-
caatgta) or highly-degenerate (Forward ttyactgtcctacctyarrrr,
Reverse tcagyataatrycatyartrya) primer pair were carried out
inatotalvolume of50mlcontaining10mMTris–HCl, 1.5mM
MgCl2, 50 mM KCl, 16.5 pmol of each primer, 0.25 mM
of each deoxynucleotide triphosphate, 0.25 U of Taq poly-
merase (Roche) and 250 ng of genomic DNA. Ampliﬁcations
were performed in a GeneAmp  PCR System 9700 thermal
cycler (Applied) following modiﬁed pan-retrovirus cycling
(31): initial 5 min denaturation step at 94 C, 3 cycles at
94 C for 30 s, 45 C for 3 min and 72 C for 1 min followed
by 35 cycles at 94 C for 30 s, 50 C for 2 min and 72 C for
1 min, followed by a 7 min ﬁnal extension step at 72 C. The
ampliﬁcation products were separated by electrophoresis on
3% agarose gel. The bands of interest were puriﬁed and cloned
in pCR  2.1-TOPO  vector using the TOPO TA Cloning  Kit
(Invitrogen). Twenty two ‘weakly-degenerate HERV-L’
clones and 24 ‘highly-degenerate HERV-L’ clones were
sequenced. A phylogenetic tree was then constructed from
these sequences using the UPGMA (absolute distance)
method.
Cell culture and differentiation
BeWo b30 human choriocarcinoma cells were cultured in
F-12K medium (Invitrogen, Carlsbad, CA) supplemented
with 10% fetal calf serum (FCS) (Invitrogen, Carlsbad,
USA), antibiotics (100 IU of penicillin/ml and 100 mgo f
streptomycin/ml) (Invitrogen, Carlsbad, CA) and 0.25 mg/
ml amphotericin B (Fungizone) (Invitrogen, Carlsbad,
USA). At 50% conﬂuence, the medium was then replaced
by one containing 50 mM forskolin (Calbiochem, Darmstadt,
Germany) or vehicle (DMSO) (Sigma, St Louis, USA),
followed by 36 h of incubation at 37 C to induce BeWo
differentiation. U937 monocytoid cells were cultured in
RPMI 1640 medium containing 10% FCS, antibiotics
(100 IU of penicillin/ml and 100 mg of streptomycin/ml)
(Invitrogen, Carlsbad, CA) and 0.25 mg/ml amphotericin B
(Fungizone) (Invitrogen, Carlsbad, USA). The cells were
seeded at a density of 5.10
5 cells per ml of a culture medium
containing 50 ng/ml of phorbol-12-myristate-13-acetate
(PMA) or vehicle (DMSO) (Sigma, St Louis, USA), followed
by 72 h of incubation at 37 C to induce U937 differentiation.
Cultures were performed in triplicate for each set of experi-
ments to assess reproducibility.
RNA samples and reverse-transcription
BeWo b30 and U937 total RNA were isolated using the
RNeasy Midi Kit including an on-column DNAse treatment
in accordance with the manufacturer’s instructions (Qiagen,
Hilden, Germany). Breast, colon, lung, prostate, testis and
uterus FirstChoice  Human Tumor/Normal Adjacent Tissue
RNA waspurchasedfrom Ambion(Austin,Texas).Thequant-
ity of RNA was measured at OD260 in a spectrophotometer and
the RNA quality was assessed with a Bioanalyzer capillary
electrophoresis device (Agilent, Palo Alto, USA). The total
RNA (5 mgo r1mg from cultured cells or commercial samples,
respectively) was reverse transcribed in a volume of 20 ml
containing 1· ﬁrst strand buffer, 0.01 M DTT, 40 U
RNaseOUT, 0.5 mM dNTP-Mix, 250 ng of random primers
(Promega, Madison, USA) and 200 U of SuperScriptII
(Invitrogen, Carlsbad, USA) according to the manufacturer’s
recommendations. Reverse-transcriptase-free reactions were
carried out to verify the absence of contaminating
genomic DNA.
Multiplex PCR
Multiplex PCRs were carried out in a total volume of 50 ml
containing 10 mM Tris–HCl, 1.5 mM MgCl2, 50 mM KCl,
10 mM (or various concentrations for the optimal concentra-
tion range determination) of optimized primer mix, 0.25 mM
of dATP, 0.25 mM of dCTP, 0.25 mM of dGTP, 0.188 mM of
dTTP, 0.062 mM of dUTP-biotin (Roche), 0.25 U of Taq
polymerase (Roche) and 5 ml of the reverse-transcription reac-
tion volume or predeﬁned copy number of cloned archetypes.
Ampliﬁcations were performed in a GeneAmp  PCR System
9700 thermal cycler as follows: initial 5 min denaturation step
at 94 C, 3 cycles at 94 C for 30 s, 45 C for 3 min and 72 C for
Figure 1. Microarray design. (A) Microarray map. The OLISA  microarray
comprises a spotting control consisting in a biotinylated oligonucleotide and a
hybridization control consisting in an oligonucleotide complementary to the
spiked target. HERV-pol probe specificity was assessed by hybridization
with biotinylated targets: (B) HML-2, (C) HML-4, (D) HML-5, (E) HERV-H,
(F) ERV-9, (G) HERV-W, (H) HERV-E4.1, (I) HERV-R and (J) HERV-L.
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2 min and 72 C for 1 min, followed by a ﬁnal 7 min extension
step at 72 C. Ampliﬁcation products were systematically
checked by electrophoresis on 3% agarose gel before the
microarray analysis.
Microarray analysis
The OLISA  microarray handling and protocol were per-
formed according to the manufacturer’s recommendations
(bioMe ´rieux, Grenoble, France). In sum: 5 ml of biotin-labeled
multiplex ampliﬁcation products were chemically denatured
for 5 min at room temperature (RT), and then hybridized on
a microarray for 60 min at 37 C in hybridization solution.
The microarrays were washed four times with 300 mlo f
washing buffer at RT. A detection solution, containing a
streptavidine–HRP conjugate, was dispensed on each micro-
array and incubated for 20 min at 25 C. The microarrays were
washed four times with 300 ml of washing buffer at RT. An
aliquot of 50 ml of staining solution containing the horseradish
peroxidase (HRP) substrate was added to each microarray and
incubated for 20 min at 25 C. The microarray image acquisi-
tion was then performed using an Apimager  densitometry
reader (bioMe ´rieux, Grenoble, France) and the data analysis
was performed using the ApiAnalyser software (bioMe ´rieux,
Grenoble, France).
Statistical analysis
HERV transcriptome analyses of in-vitro differentiation
models and tumor/normal adjacent tissue RNA were per-
formed in triplicate. The statistical analysis was performed
using Student’s t-test. The mean values of two groups (mock-
treated cells versus treated cells or normal tissue versus
tumoral tissue) were considered to be signiﬁcantly different
if P < 0.05.
RESULTS
Probe design and validation
The RT moieties of retroviral pol genes encompass two
highly conserved and closely positioned regions corres-
ponding to the VLPQG and YV/MDDI/V/LL reverse-
transcriptase functional motifs. This area was selected to
design a multiplex ampliﬁcation system dedicated to the
study of nine HERV families. The alignments of the collected
sequences led to the determination of the probability of
the presence of the 4 nt on each pol consensus position
(pol sequence matrix). In this way, probes corresponding to
the most conserved part of the VLPQG–YV/MDDI/V/LL inner
region of each HERV family were designed. Probe speciﬁcity
was conﬁrmed by the absence of cross-reactions after hybrid-
izationwith synthetic biotinylated targets(Figure1B–J).How-
ever, the sequence variability existing within each HERV
family may result in imperfect complementarities between
probes and their homologous targets. Therefore, we evaluated
the impact of possible mismatches on target detection using
mutation-containing probes. Equivalent signals were meas-
ured for HML-2 and HML-2 1MM probes and a weaker
but signiﬁcant signal was measured for HML-2 2MM probes.
Similarly, HERV-H and HERV-H 1MM probes displayed
comparable signals. Conversely, no signal was detected
using HML-2 probes containing more than two mutations.
Degenerate primer design
The primer design was based on the determination of the
nucleic acid sequence composition corresponding to the
VLPQG and YV/MDDI/V/LL motifs. This constituted a ration-
ale for determining the primer degeneracy. It should be noted
that the linear increase of the primer degeneracy level is det-
rimental to ampliﬁcation efﬁciency (sensitivity) due to the
geometric increase in combinatory possibilities. The ampli-
ﬁcation product diversity was used to evaluate the impact of
the degeneracy criteria on PCR behavior. The HERV-L family
was chosen as a model because it contains the highest number
of copies (990) among the nine HERV families and is sufﬁ-
ciently divergent (22%) to discriminate between cloned PCR
products. Brieﬂy, PCRs were performed on genomic DNA
either with a weakly-degenerate HERV-L-speciﬁc primer
pair hereafter referred to as Dg4 (level of degeneracy ¼ 4
for each primer) or with a highly-degenerate HERV-L-speciﬁc
primer pair referred to as Dg128 (level of degeneracy ¼ 128
for each primer) and the PCR products were cloned and
sequenced. No bias was obtained using either the Dg128 or
the Dg4 primer sets. Firstly, 87.5% (21/24) and 95.5% (21/22)
of the sequenced populations consist of distinct clones for
Dg128 and Dg4, respectively. Secondly, Dg128 and Dg4 amp-
liﬁcation products were found uniformly distributed through-
out the phylogenetic tree (Figure 2). In the Dg4 primer set, the
lowest frequency observed for a nucleotide position was 83%
of that present in the whole HERV-L population alignment.
Consequently, for each family, we designed primers by min-
imizing their level of degeneracy as follows: a single nucle-
otide or a combination of nucleotides, representing from 100
to 80% of the base frequency observed in the whole popula-
tion, was determined for each primer position. This led to a
mean degeneracy level of 13 ± 16 for the 18 primers. The 80%
rule was empirically bypassed in two cases in order to avoid an
alteration of the assay sensitivity. For HERV-W, the 78%
frequency tolerated for one position of the reverse primer
made it possible to halve the primer pair degeneracy. For
HERV-E4.1, a 75% frequency tolerated for one position of
the forwardprimertogetherwitha67%frequencytoleratedfor
one position of the reverse primer made it possible to keep the
primer pair degeneracy comparable with other HERV primer
pairs (Table 1).
Degenerate primer mix optimization
In a second step, we developed a complex mix of degenerate
primers in order to perform a multiplex PCR. The heterogen-
eity of the level of degeneracy within a primer pair and the
heterogeneity of intrinsic ampliﬁcation efﬁciencies of primer
pairs were taken into account. The primer mix composition
was established empirically by PCR ampliﬁcation of a syn-
thetic model consisting of nine cloned HERV-pol archetypes.
The ampliﬁcation performances were compared with a refer-
ence equimolar primer mix. An iterative procedure was
applied, by constituting several primer mix generations, to
deﬁne a primer mix resulting in signals as close to each
other as possible (Table 1, Figure 3A). The average intensity
for the nine HERV families was used as a reference and all
e46 Nucleic Acids Research, 2006, Vol. 34, No. 6 PAGE 4 OF 10intensities measured were expressed as a percentage of this
reference. In this way, the multiplex ampliﬁcation using the
equimolar primer mix resulted in signal intensities widely
dispersed around the 100% reference value. The extreme
values were 0% for HERV-H and 459% for HML-4. This
overall range was dramatically reduced with the ﬁnal version
of the complex primer mix, ranging from 43% for HERV-R to
240% for HML-4. More speciﬁcally, six out of nine signals
were improved (HML-4, HML-5, HERV-H, HERV-W,
HERV-E4.1 and HERV-L), two out of nine signals were
unchanged (ERV-9 and HERV-R) and one out of nine was
slightly degraded (HML-2: 55% for the equimolar primer mix
and 179% for the complex primer mix). Taken together, these
results demonstrated that empirical determination of primer
quantities in a complex mix compensated for both degeneracy
variation in primer pairs and intrinsic ampliﬁcation efﬁciency
differences. Hence, the complex primer mix developed
enabled an equivalent multiplex PCR ampliﬁcation of nine
HERV families. We also studied the impact of the primer
concentration on the ampliﬁcation efﬁciency of each HERV
archetype. We ampliﬁed 10
6 copies of each archetype separ-
ately with an optimized primer mix concentration range
(Figure 3B). The band intensity measurement on the agarose
gel electrophoresis pattern led to the determination of an
optimal primer mix concentration range in the ﬁnal reaction
volume between 8 and 13 mM. Primer concentrations above
15 mM led to a decrease in the PCR ampliﬁcation efﬁciency.
Multiplex amplification characterization
In order to check whether the deﬁned ampliﬁcation system
co-ampliﬁed the nine targets on a 100-fold range of copy
numbers efﬁciently, we performed the ampliﬁcation of
10-fold serial dilutions of an equimolar mix of archetypes
(Figure 4A). These ampliﬁcations led to signal variations cor-
related with target amounts for all HERV archetypes, i.e. with
a dose-effect relationship, although with variable dynamic
ranges. The broadest dynamic ranges were found for
HML-4 (signal intensities from 1773 to 10 320) and
HERV-E4.1 (signal intensities from 781 to 9500) and the
narrowest was found for HERV-H (signal intensities from
1043 to 1675). However, HML-4 and HERV-H had linear
dynamic ranges (R > 0.99). Conversely, although it had one
of the broadest dynamic ranges, HERV-E4.1 was exponential
rather than linear (R   0.73). Nevertheless, all these dynamic
ranges were found to be compatible with a further quantitation
objective. Furthermore, we evaluated the efﬁciency of the
quantitation process for unbalanced target quantities. To
this end, four different mixtures of HERV-pol archetypes
Table 1. Degenerate primer sequences and primer mix composition








HML-2 TRGAAAGTGTTRCCTCARGGA 8 0.51 CACAYAAAATATYATCAAYAYA 16 1.02
HML-4 TGGAAAGTCCTACCACAAGGC 1 0.03 TGCAGAGGAGATCATCCATGTA 1 0.03
HML-5 TRGAAAGTRCTTCCTSAARGR 32 1.02 CYAGTARRATATCATCCATAAA 8 0.51
HERV-H TGGRCTGTRCTGCYRCAAGGY 32 2.03 AAAGWAGAAGSTCRTCAAWATA 16 1.02
ERV-9 GTCTTGCCHCAAGGGTTT 3 0.13 AGTAAATCATCCACATAYTGAAG 2 0.13
HERV-W TGGACTGTTTTACCCCAAGGG 1 0.13 AAgTAAATYATCCMYRTACYRA
c 64 1.02
HERV-E4.1 TGGACCsRGCYTCCCCAARGG
b 16 1.02 CCAGCARRAGGTCATCaAYSTA
d 16 1.02
HERV-R TGGACTAGTCTCCCACAAGGG 1 0.06 CCAAAAGAAGGTTGTCTATGTA 1 0.06
HERV-L TTTACTGTCCTACYTCAGGGR 4 0.25 TCARCATAATGYCATCAATGTA 4 0.51
aLevel of degeneracy.
b‘s’ represents 75% of the base(s) observed at that position in the whole population.
c‘g’ represents 78% of the base(s) observed at that position in the whole population.
d‘a’ represents 67% of the base(s) observed at that position in the whole population.
Figure 2. UPGMA (absolute distance) phylogenetic tree of HERV-L ampli-
fication products obtained by PCR on genomic DNA. Amplicons generated
using weakly-degenerate primers (degeneracy level ¼ 4) are depicted in grey
and amplicons generated using strongly-degenerate primers (degeneracy
level ¼ 128) are depicted in black.
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each archetype, 10
5 and 10
6 copies, respectively. Mix C con-
tained 10
5 copies of each HERV archetype as for mix A,
except for HML-4 and HERV-E4.1 for which the amounts
were raised to 10
6 copies. Mix D contained 10
6 copies of
each HERV archetype as for Mix B, except for HML-4 and
HERV-E4.1 for which the amounts were reduced to 10
5 copies
(Figure 4B). The ability of the assay to amplify and to detect
the targets independently was evaluated by calculating, for
each HERV, the C/A and D/B ratios of the intensities meas-
ured. C/A and D/B ratios close to 1 were expected for targets
with identical quantities under different experimental condi-
tions. In this way, HML-2, HML-5, HERV-H, ERV-
9 HERV-W, HERV-R and HERV-L displayed C/A and D/
B ratios ranging from 0.80 to 1.43 and 0.87 to 1.39, respect-
ively. Hence, this demonstrated that the ampliﬁcation of these
seven targets was only affected slightly by the altered amount
ofthetwoothertargets. Conversely,theincrease intheHML-4
and HERV-E4.1 copy numbers under experimental condition
C was correlated with a C/A ratio of 2.64 and 2.06, respect-
ively. A reverse alteration of the ratio was observed when the
HML-4 and HERV-E4.1 copy numbers were reduced, with the
D/B ratio falling to 0.35 and 0.38, respectively. Altogether,
these results conﬁrmed the dose-effect relationship previously
highlighted and strongly suggested that the ampliﬁcation
system developed could enable the detection of the variation
in HERV sequence quantity between different samples.
HERV transcriptome analysis of in-vitro differentiation
models and tumor/normal adjacent tissue RNAs
MD-PCR/OLISA was used for comparative studies of in-vitro
cell differentiation models and biological samples. In order to
evaluate the reproducibility of the assay, three biological rep-
licates were performed from independent cultures of BeWo,
forskolin-induced BeWo, U937 and PMA-stimulated U937
cells.Thecoefﬁcients ofvariation (CV¼SD/mean)calculated
for BeWo cells ranged from 3.3 to 17%, the forskolin-treated
BeWo cell CVs ranged from 0.5 to 22.3%, the U937 cell CVs
ranged from 3.3 to 24.3% and the PMA-treated U937 cell CVs
ranged from 0.5 to 12.2%.
In BeWo cells, forskolin had a signiﬁcant prominent effect
on (i) HML-2, HML-5, and HERV-E4.1 whose expression
decreased and on (ii) HERV-W and HERV-R whose expres-
sion increased (Figure 5A). In U937 cells, PMA only down-
regulated HML-5 and upregulated HERV-R expressions
Figure 3. Complex primer mix optimization. (A) Equimolar versus complex
primer mix amplification product analysis on microarray. A target mix con-
sisting of 10
6 copies of each cloned archetype was amplified either with an
equimolar mix of degenerate primers (open triangle and dashed line) or a
complex primer mix of degenerate primers (open circle and black line). Band
intensities were measured using the Photo-Capt  software (Vilbert-lourmat,
Marne-la-Valle ´e, France). The average intensity for the nine HERV families
was used as a reference and all intensities measured were expressed as a
percentage of this reference. (B) Optimal complex primer mix concentration
range. Each cloned archetype and U937 cDNA were amplified with various
final primer mix concentrations (HML-2 large indent, HML-4 open rhombus,
HML-5 star, HERV-H open triangle, ERV-9 cross, HERV-W open circle,
HERV-E4.1 plus, HERV-R open square, HERV-L small indent and cDNA
black rhombus).
Figure 4. Complex primer mix characterization. (A) PCR co-amplification of
various target quantities with a complex primer mix. PCRs were performed on




5 copies of each HERV archetype,
respectively. The mean and standard deviation were calculated from experi-
ments conducted in triplicate. (B) Amplification of unbalanced target quanti-
ties. Condition A: 10
5 copies of each target, condition B: 10
6 copies of each
target, condition C: 10
5 copies of each target, except HML-4 and HERV-E4.1
(10
6 copies) and condition D: 10
6 copies of each target, except HML-4 and
HERV-E4.1 (10
5 copies). Black bars represent the C/A ratio of the intensities
measured and grey bars represent D/B ratio of the intensities measured. Ratios
were calculated from the means of experiments conducted in triplicate. The
continuous black line represents a reference value of 1.
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of HERV expression in BeWo and U937 cells are speciﬁc.
Surprisingly, no signal was detected for HML-4 in native or
differentiated BeWo and U937 cells. All of the tumor types
also demonstrated unique differential expression proﬁles. The
HML-4 family remained untraceable in any of the six sample
pairs. Reproductive tissue tumors exhibited unique expression
proﬁles with breast-derived tumor demonstrating statistically
signiﬁcant increases in HML-2, HML-5, HERV-W, HERV-
E4.1, HERV-R and HERV-L (Figure 5C), uterine tumor
demonstrating HERV-R and HERV-L upregulation
(Figure 5D), testicular tumor demonstrating HML-2,
HERV-W and HERV-E4.1 upregulation and ERV-9 down-
regulation (Figure 5E), and prostate tumor demonstrating
Figure 5. MD-PCR/microarray HERV transcriptome analysis of in-vitro differentiation models and paired normal/tumoral RNA. (A) Forskolin-treated BeWo
b30 cells, (B) PMA-treated U937 cells, (C) breast, (D) uterus, (E) testis, (F) prostate, (G) lung and (H) colon. Each bar represents a percentage of signal intensity
variation calculated from experiments conducted in triplicate between the differentiated cells or the tumoral tissue and the mock-treated cells or the normal tissue,
respectively.The1symbolindicatesthatasignalwasdetectedforthedifferentiatedcellsorthetumoraltissue,whereasnosignalwasdetectedforthecorresponding
mock-treated cells or normal tissue. The Student’s t-test statistical significance (P < 0.05) was indicated by *.
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(Figure 5F). Additional tumors, such as those derived from
lung and colon also demonstrated unique expression patterns.
Lung tumor exhibited an increase in HML-2 transcription
and a decrease in HERV-E4.1 expression (Figure 5G) whereas
only HERV-H expression increased in colon tumor
(Figure 5H). In this way, each cell type or tissue exhibited
a unique differential HERV expression proﬁle as opposed to a
general increase or decrease in expression.
DISCUSSION
Diagnostic methods have to compromise between speciﬁcity
and sensitivity, according to the assumed risk of false negative
and false positive results, respectively. The biological question
addressed in this paper involved two additional problems due
to (i) the number of variable loci within each HERV family
and (ii) the need for a balanced ampliﬁcation of all families.
Hence, the exhaustiveness and sensitivity of the overall assay
are closely linked. This study relates to the identiﬁcation of
general rules allowing the deﬁnition of a quantitative assay
based on a MD-PCR, coupled with the OLISA  microarray
detection format.
In the OLISA  detection format, the exhaustiveness of the
capture probe relies upon the empirical selection of the most
conserved region, i.e. the consensus, and the experimentally
observed ability to tolerate the hybridization of slightly diver-
gent targets as shown using mismatch-containing probes. In
this way, the one to two authorized variable sites would make
it possible to hybridize not strictly identical loci, e.g. contain-
ing polymorphic sites, without generating cross-reactions
between different HERV families as depicted. Similarly, no
cross-reaction resulted from the use of degenerate ampliﬁca-
tion primers (see below) as validated using pol archetypes.
Additionally, a single band of  130 bp detected by pol probes
was observed in the agarose gel electrophoresis of MD-PCR
products derived from sixteen different RNA samples,
strongly suggesting the absence of non-retroviral sequence
ampliﬁcation (data not shown).
In the ampliﬁcation step, high primer degeneracy should
lead to exhaustive but poorly sensitive ampliﬁcation and, con-
versely, low primer degeneracy should lead to a poorly
exhaustive but sensitive ampliﬁcation of an HERV family,
as highlighted by Forsman et al. (25). We deﬁned three critical
ampliﬁcation criteria enabling the quantitation of pol gene
transcripts of nine HERV families, (i) the primer degeneracy
determining exhaustiveness, sensitivity and speciﬁcity, (ii) the
concentration of each primer determining sensitivity and bal-
anced ampliﬁcationsand(iii)thetotal amount ofprimersinthe
ampliﬁcation mixture determining sensitivity. The impact of
primer degeneracy on the diversity of the generated amplicons
was assessed using the complex HERV-L family. The two
experimental populations derived from DNA ampliﬁcation
using either low or high-degenerate HERV-L primers depicted
the whole HERV-L population similarly. This enabled us to
propose an acceptability threshold to design each primer posi-
tion, deﬁned as follows: each single nucleotide or combination
of nucleotides may represent at least 80% of the base(s)
observed at that position in the whole population. In order
to minimize the degeneracy level, a lower frequency could
be tolerated for a single primer position. In our assay, this
concerned 3out18 primers andthe lowestfrequency was67%.
The degeneracy heterogeneity within each single primer
pair may impair the ampliﬁcation efﬁciency due to unbalanced
availability of reverse versus forward primers toward a given
target. This was efﬁciently counterbalanced by increasing the
relative concentration of the more degenerate primer. How-
ever, for a primer pair, no linear relationship could be estab-
lished between the relative degeneracy levels and the optimal
primer concentration ratio, as previously mentioned (40). In
addition, primer pair concentration was increased for the pri-
mer pairs generating weak signals and was decreased for the
primer pairs generating strong signals, in order to compensate
for their intrinsically heterogeneous ampliﬁcation efﬁciencies.
This result was found to agree with rules proposed for the
development of multiplex PCR (41). The optimal overall pri-
mer concentration was found to range between 8 and 13 mM,
10 times higher than in conventional PCR. This MD-PCR
primer concentration lies between the 20 mM concentrations
described in the original pan-retrovirus degenerate PCR
protocol (26) and the 0.5–4 mM concentration range described
in various multiplex PCR assays (41–43).
The MD-PCR/OLISA assay detected at least 10
5 copies of
each individual archetype in an equimolar mix of all arche-
types. This was in the same range as general retroviral PCRs
developed by Tuke et al. and Seifarth et al. (about 1–2.10
6
copies) (25,27,30). This sensitivity is lower than that observed
in single-target RT–PCR/ELOSA assays [50 copies, for a
review, see (44)], due to primer degeneracy, and lower than
that observed in HERV broadly targeted real-time reverse-
transcription PCRs (1–10 copies) (25). Nevertheless, this sen-
sitivity is compatible with the detection of moderately
expressed genes (10 copies per cell) in view of the nucleic
acid quantities used for this assay ( 5.10
5 copies in 0.25 mg
RNA). A dose-effect relationship was observed within the
10
5–10
7 target range. In addition, a 10-fold difference in target
concentrations did not affect the overall ampliﬁcation efﬁci-
ency of each distinct target. The robustness of the MD-PCR/
OLISA method was assessed on biological replicates consis-
ting of independent RNA extractions, cDNA syntheses,
MD-PCR ampliﬁcations and OLISA detections. The calcu-
lated coefﬁcients of variation ranged from 0.5 to 24.3%.
These CVs were found to be comparable to those described
using single-target PCR or RT–PCR ampliﬁcations coupled
with ELOSA monodetection, from 3.0 to 24% (44,45). Hence,
the reliability of the MD-PCR/OLISA method is suitable for
use as a clinical assay. Moreover, this indicates that the use of
both accurate RNA quantitation and quality assessment of
RNAs are sufﬁcient to establish total RNA normalization as
a suitable method, as previously suggested (46).
We thus investigated the HERV transcriptome modiﬁca-
tions occurring in the cell differentiation process and the
malignant transformation process. The human choriocar-
cinoma BeWo cell line undergoes fusion and extensive
morphological differentiation, mimicking cytotrophoblast
differentiation into syncytiotrophoblasts, following their
treatment with cyclic AMP metabolism effectors (47). With
the MD-PCR/OLISA assay we conﬁrmed the upregulation
of HERV-W and HERV-R in forskolin-treated BeWo Cells
(8,48). Similarly, we conﬁrmed HERV-R upregulation
in PMA-treated U937 cells (49), an inducible monocyte
e46 Nucleic Acids Research, 2006, Vol. 34, No. 6 PAGE 8 OF 10differentiation model. However, we did not ﬁnd signiﬁcant
increases in HERV-W and HERV-H, as previously shown
with RT–PCR using pol and gag primer sets, respectively
(21). This may reﬂect the use of poorly representative pol
and gag primers, inducing increased sensitivity but not reﬂect-
ing the overall behavior of each family. The MD-PCR/OLISA
analysis ofnormal/tumoral RNA samples led todiscriminating
proﬁles between tissues as observed for the two differentiated
cell lines. Within these proﬁles, the observed variations were
in agreement with previous independent studies. In this way,
the MD-PCR/OLISA assay demonstrated an increase in
HML-2 expression in breast tumors (16) and in testicular
tumors (50), in HERV-E4.1 expression in prostate tumors
(15) and in HERV-H expression in colon tumors (51,52).
Surprisingly, no HML-4 expression was detected as opposed
to the ubiquitous expression described (24,31), questioning
the exhaustiveness/speciﬁcity features of both systems. This
discrepancy was previously observed in northern blot
analyses, showing disparate HML-4 expressions in the lung
and placenta (53,54). This illustrates that none of the existing
systemsare probably exhaustive andthatfurther developments
or combinations of assays will be necessary for a comprehens-
ive evaluation of HERV expression. Nevertheless, all proﬁles
were found to be different for the six paired tissues and the two
differentiation models. This suggests that the processes
involved in the modulation of HERV transcription in the
course of (de)differentiation are tissue-speciﬁc, as previously
suggested (52). Although, it is not known whether identical or
different locus subsets of one given HERV family were mobil-
ized, these results demonstrate that the pol-based global
approach is valid as a proﬁling tool, as similarly demonstrated
for the brain (55). In conclusion, the reliable MD-PCR/OLISA
assay we developed provides general rules for the design of
multiplex degenerate PCR applications and an alternative
system for HERV transcription analysis which may be useful
in tumor phenotyping.
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